Non-complement-binDing de novo donor-specific anti-HLA antibodies and kidney allograft survival

Journal of the American Society of Nephrology

Volumn 27, Issue 2, 2016, Pages 615-625

  Guidicelli, Gwendaline ^a,b,c   Guerville, Florent ^b,c,d   Lepreux, Sébastien ^b   Wiebe, Chris ^e   Thaunat, Olivier ^f,g,h   Dubois, Valérie ⁱ   Visentin, Jonathan ^a,b,c   Bachelet, Thomas ^b,c,d   Morelon, Emmanuel ^f,g,h   Nickerson, Peter ^a   Merville, Pierre ^b,c,d   Taupin, Jean Luc ^a,b,c   Couzi, Lionel ^b,c,d  

^a Departments of Immunology   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c CNRS Bordeaux Segalen University   (France)

^d Nephrology Transplantation Dialysis   (France)

^e UNIVERSITY OF MANITOBA   (Canada)

^f HOSPICES CIVILS DE LYON   (France)

^g INSERM   (France)

^h UNIVERSITÉ DE LYON   (France)

ⁱ French Blood Center   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BELATACEPT; COMPLEMENT COMPONENT C1Q; CYCLOSPORIN A; DACLIZUMAB; HLA ANTIBODY; MYCOPHENOLATE MOFETIL; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIBODY; COMPLEMENT; HLA ANTIGEN; PROTEIN BINDING;

ADULT; ARTICLE; DELAYED GRAFT FUNCTION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK FACTOR; ALLOGRAFT; ANTIBODY SPECIFICITY; DONOR; IMMUNOLOGY; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; ALLOGRAFTS; ANTIBODIES; ANTIBODY SPECIFICITY; COMPLEMENT SYSTEM PROTEINS; FEMALE; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEIN BINDING; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE DONORS;

EID: 84970937367     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014040326     Document Type: Article

References (40)

1. Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, Kaplan B, Halloran PF: Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 9: 2520-2531, 2009
2. Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Grande J, Halloran P, Hunsicker L, Mannon R, Rush D, Matas AJ: Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 90: 68-74, 2010
3. Sellarés J, de Freitas DG,MengelM, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF: UnderstanDing the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 12: 388-399, 2012
4. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-Boissel C: Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 21: 1398-1406, 2010
5. Gloor JM, Winters JL, Cornell LD, Fix LA,DeGoey SR, Knauer RM,Cosio FG, Gandhi MJ, Kremers W, Stegall MD: Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 10: 582-589, 2010
6. Ntokou I-SA, Iniotaki AG, Kontou EN, Darema MN, Apostolaki MD, Kostakis AG, Boletis JN: Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: High immunogenicity of HLA class II graft molecules. Transpl Int 24: 1084-1093, 2011
7. Cooper JE,Gralla J, Cagle L, Goldberg R, Chan L,Wiseman AC: Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 91: 1103-1109, 2011
8. Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, Catrou PG, Bolin P, KendrickWT, Kendrick SA, Harland RC, Terasaki PI: Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 95: 410-417, 2013
9. Wiebe C, Gibson IWI, Blydt-Hansen TDT, Karpinski M, Ho J, Storsley LJL, Goldberg A, Birk PEP, Rush DND, Nickerson PWP: Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 12: 1157-1167, 2012
10. Liefeldt L, Brakemeier S, Glander P, Waiser J, Lachmann N, Schönemann C, Zukunft B, Illigens P, Schmidt D, Wu K, Rudolph B, Neumayer HH, Budde K: Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 12: 1192-1198, 2012
11. de Kort H, Willicombe M, Brookes P, Dominy KM, Santos-Nunez E, Galliford JW, Chan K, Taube D, McLean AG, Cook HT, Roufosse C: Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant 13: 485-492, 2013
12. Caro-Oleas JL,González-EscribanoMF,Gentil-GovantesMÁ, Acevedo MJ, González-Roncero FM, Blanco GB, Núñez-Roldán A: Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation. Transplantation 94: 338-344, 2012
13. Bartel G, Regele H, Wahrmann M, Huttary N, Exner M, Hörl WH, Böhmig GA: Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 8: 2652-2660, 2008
14. Mizutani K, Terasaki P, Hamdani E, Esquenazi V, Rosen A, Miller J, Ozawa M: The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 7: 1027-1031, 2007
15. Freitas MCS, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, Briley KP, Haisch CE, Bolin P, Parker K, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI: The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 95: 1113-1119, 2013
16. Hönger G, Hopfer H, Arnold M-L, Spriewald BM, Schaub S, Amico P: Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation 92: 41-47, 2011
17. Chen G, Sequeira F, Tyan DB: Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulinGstrength on single antigen beads. HumImmunol 72: 849-858, 2011
18. Lachmann N, Todorova K, Schulze H, Schönemann C: Systematic comparison of four cell-and Luminex-based methods for assessment of complement-activating HLA antibodies. Transplantation 95: 694-700, 2013
19. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB: C1qfixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 91: 342-347, 2011
20. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Frémeaux-Bacchi V, Méjean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana J-P, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X: Complement-binDing anti-HLA antibodies and kidney-allograft survival. N Engl JMed 369: 1215-1226, 2013
21. Otten HG, Verhaar MC, Borst HPE, Hené RJ, van Zuilen AD: Pretransplant donor-specific HLA class-I and-II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 12: 1618-1623, 2012
22. AnthonyRM,Nimmerjahn F: The role of differential IgGglycosylation in the interaction of antibodies with FcgRs in vivo. Curr Opin Organ Transplant 16: 7-14, 2011
23. Visentin J, VigataM, Daburon S, Contin-Bordes C, Frémeaux-Bacchi V, Dromer C, Billes M-A, Neau-Cransac M, Guidicelli G, Taupin J-L: Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays. Transplantation 98: 625-631, 2014
24. Schnaidt M, Weinstock C, Jurisic M, Schmid-Horch B, Ender A, Wernet D: HLA antibody specification using single-antigen beads-a technical solution for the prozone effect. Transplantation 92: 510-515, 2011
25. Guidicelli G, Anies G, Bachelet T, Dubois V, Moreau J-F, Merville P, Couzi L, Taupin J-L: The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients. Transpl Immunol 29: 17-21, 2013
26. Stegall MD, Chedid MF, Cornell LD: The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 8: 670-678, 2012
27. Le Friec G, Kemper C: Complement: Coming full circle. Arch Immunol Ther Exp (Warsz) 57: 393-407, 2009
28. Hirohashi T, Chase CM, Della Pelle P, Sebastian D, Alessandrini A, Madsen JC, Russell PS, Colvin RB: A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 12: 313-321, 2012
29. Hidalgo LG, Sis B, Sellares J, Campbell PM, Mengel M, Einecke G, Chang J,Halloran PF: NK cell transcripts andNK cells in kidney biopsies from patients with donor-specific antibodies: Evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 10: 1812-1822, 2010
30. Zhang X, Reed EF: Effect of antibodies on endothelium. Am J Transplant 9: 2459-2465, 2009
31. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM: Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11: 2405-2413, 2011
32. Haas M, Montgomery RA, Segev DL, Rahman MH, Racusen LC, Bagnasco SM, Simpkins CE, Warren DS, Lepley D, Zachary AA, Kraus ES: Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 7: 576-585, 2007
33. Loupy A, Suberbielle-Boissel C, Hill GS, Lefaucheur C, Anglicheau D, Zuber J,Martinez F, Thervet E,Méjean A, Charron D, Duong van Huyen JP, Bruneval P, LegendreC,Nochy D:Outcome of subclinical antibodymediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 9: 2561-2570, 2009
34. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC: Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 331: 810, 2005
35. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl JMed 357: 2562-2575, 2007
36. Scornik JC,GuerraG, Schold JD, Srinivas TR,DragunD,Meier-Kriesche HU: Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant 7: 1808-1814, 2007
37. Fine RN, Becker Y, De Geest S, Eisen H, Ettenger R, Evans R, Rudow DL, McKay D, Neu A, Nevins T, Reyes J, Wray J, Dobbels F: Nonadherence consensus conference summary report. Am J Transplant 9: 35-41, 2009
38. Couzi L, Araujo C, Guidicelli G, Bachelet T, Moreau K, Morel D, Robert G, Wallerand H, Moreau J-F, Taupin J-L, Merville P: Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay. Transplantation 91: 527-535, 2011
39. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Baldwin WM 3rd, Bracamonte ER, Broecker V, Cosio F, Demetris AJ, Drachenberg C, Einecke G, Gloor J, Glotz D, Kraus E, Legendre C, Liapis H, Mannon RB, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Rodriguez ER, Seron D, Seshan S, Suthanthiran M, Wasowska BA, Zachary A, Zeevi A: Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 10: 464-471, 2010
40. Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MCR, David DSR, David-Neto E, Bagnasco SM, Cendales LC, Cornell LD, Demetris AJ, Drachenberg CB, Farver CF, Farris AB 3rd, Gibson IW, Kraus E, Liapis H, Loupy A, Nickeleit V, Randhawa P, Rodriguez ER, Rush D, Smith RN, Tan CD, Wallace WD, Mengel M; Banff meeting report writing committee: Banff 2013meeting report: Inclusion of c4dnegative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 14: 272-283, 2014